Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective.
1 . An ophthalmic composition comprising an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of said drug in water, said solubility being measured at about 25° C. and at pH of about 7-7.5.
2 . The composition of claim 1 , wherein the concentration is in a range from about 10 to about 1000 times the solubility of said drug in water, and the solubility is in a range from about 0.0001 to about 0.05 mg/mL.
3 . The composition of claim 1 , wherein the concentration is in a range from about 100 to about 500 times the solubility of said drug in water, and the solubility is in a range from about 0.0001 to about 0.05 mg/mL.
4 . The composition of claim 1 , wherein the ophthalmic drug comprises a compound having Formula I or II
wherein R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, C 1 -C 10 alkoxy groups, unsubstituted C 1 -C 10 linear or branched alkyl groups, substituted C 1 -C 10 linear or branched alkyl groups, unsubstituted C 3 -C 10 cyclic alkyl groups, and substituted C 3 -C 10 cyclic alkyl groups.
5 . The composition of claim 1 , wherein the ophthalmic drug comprises a compound having Formula III
6 . The composition of claim 1 , wherein the ophthalmic drug is selected from the group consisting of anti-inflammatory agents, anti-infective agents, anti-allergic agents, antihistamines, antiproliferative agents, anti-angiogenic agents, anti-oxidants, antihypertensive agents, neuroprotective agents, cell receptor agonists, cell receptor antagonists, immunomodulating agents, immunosuppressive agents, intraocular lowering agents, α 2 -adrenergic receptor agonists, β 1 -adrenergic receptor antagonists, carbonic anhydrase inhibitors, cholinesterase inhibitor miotics, prostaglandins and prostaglandin receptor agonists, mast cell degranulation inhibitors (mast cell stabilizers), thromboxane A 2 mimetics, protein kinase inhibitors, prostaglandin F derivatives, prostaglandin F 2α receptor antagonists, cyclooxygenase-2 inhibitors, muscarinic agents, and combinations thereof.
7 . The composition of claim 6 , wherein the composition is an aqueous suspension.
8 . The composition of claim 7 , wherein the ophthalmic drug is in the form of particles having a size less than about 1 micrometer.
9 . A method for preparing an ophthalmic composition, the method comprising: (a) adding a predetermined amount of an ophthalmic drug to a predetermined amount of a surfactant and an amount of an ophthalmically acceptable carrier; and (b) mixing the drug, the surfactant, and the carrier together to produce the composition, wherein the ophthalmic drug has a low solubility in water, the drug is in a form of particles less than about 1 μm, the amount of the carrier is sufficient to produce a desired final concentration of the drug, the ophthalmic drug is present at a concentration from about 3 to about 7000 times a solubility of the drug in water, the solubility being measured at about 25° C. and at pH of about 7-7.5, and the amount of the drug in a volume administered to a subject is non-toxic to the subject.
10 . A method for treating, controlling, or preventing a condition of an eye of a subject with an ophthalmic active ingredient, the method comprising administering topically to an ocular surface of the subject a volume from about 1 to about 15 microliter of a composition that comprises the ophthalmic active ingredient, wherein the ophthalmic active ingredient has a low solubility in water and is present at a concentration from about 3 to about 7000 times the solubility of said active ingredient in water, said solubility being measured at about 25° C. and at pH of about 7-7.5, and the amount of said drug in said volume is non-toxic to said subject.
11 . The method of claim 10 , wherein the concentration is in a range from about 10 to about 1000 times the solubility of said drug in water, and the solubility is in a range from about 0.0001 to about 0.05 mg/mL.
12 . The method of claim 10 , wherein the concentration is in a range from about 100 to about 500 times the solubility of said drug in water, and the solubility is in a range from about 0.0001 to about 0.05 mg/mL.
13 . The method of claim 10 , wherein the ophthalmic active ingredient comprises a compound having Formula I or II
wherein R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, C 1 -C 10 alkoxy groups, unsubstituted C 1 -C 10 linear or branched alkyl groups, substituted C 1 -C 10 linear or branched alkyl groups, unsubstituted C 3 -C 10 cyclic alkyl groups, and substituted C 3 -C 10 cyclic alkyl groups.
14 . The method of claim 10 , wherein the ophthalmic active ingredient comprises a compound having Formula III
15 . The method of claim 14 , wherein the condition comprises ocular inflammation or dry eye.
16 . The method of claim 10 , wherein the ophthalmic active ingredient is selected from the group consisting of anti-inflammatory agents, anti-infective agents, anti-allergic agents, antihistamines, antiproliferative agents, anti-angiogenic agents, anti-oxidants, antihypertensive agents, neuroprotective agents, cell receptor agonists, cell receptor antagonists, immunomodulating agents, immunosuppressive agents, intraocular lowering agents, α 2 -adrenergic receptor agonists, β 1 -adrenergic receptor antagonists, carbonic anhydrase inhibitors, cholinesterase inhibitor miotics, prostaglandins and prostaglandin receptor agonists, mast cell degranulation inhibitors (mast cell stabilizers), thromboxane A 2 mimetics, protein kinase inhibitors, prostaglandin F derivatives, prostaglandin F 2α receptor antagonists, cyclooxygenase-2 inhibitors, muscarinic agents, and combinations thereof.
17 . The method of claim 16 , wherein the composition is an aqueous suspension.
18 . The method of claim 17 , wherein the volume of the composition administered to the ocular surface is from about 5 to about 15 microliter.
19 . The method of claim 10 , wherein the volume of the composition administered to the ocular surface is from about 5 to about 15 microliter.
20 . The method of claim 14 , wherein the volume of the composition administered to the ocular surface is from about 5 to about 15 microliter.